KT-621 Development Plan Enables Efficient Path to Registration
Across All Type 2 Diseases

                                                                               Ph3
                                                          Ph2b AD              Dose     Ph3: AD (Initial),
                                                          Dose Ranging                  EoE, CSU, PN, BP
                                                           Ongoing
                                                   Data expected by mid-2027

      Ph1 HV                  Ph1b AD
      SAD-MAD             Single Arm, Open Label

     ✓ Complete              ✓ Complete                                        Ph3
                                                       Ph2b Asthma             Dose   Ph3: Asthma (Initial),
                                                          Dose Ranging                  COPD, CRSwNP
                                                            Initiated
                                                     Data expected late-2027

Initial parallel Phase 2b trials in moderate to severe AD and asthma have the potential to
support subsequent Phase 3 trials across multiple dermatology, GI, and respiratory indications
                                                                                                               17
